Compare BYND & IMMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BYND | IMMX |
|---|---|---|
| Founded | 2009 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 346.2M | 306.2M |
| IPO Year | 2018 | 2021 |
| Metric | BYND | IMMX |
|---|---|---|
| Price | $0.66 | $8.72 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 7 | 4 |
| Target Price | $1.70 | ★ $17.25 |
| AVG Volume (30 Days) | ★ 29.9M | 675.2K |
| Earning Date | 05-06-2026 | 03-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 53.80 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $326,452,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.50 | $1.34 |
| 52 Week High | $7.69 | $11.61 |
| Indicator | BYND | IMMX |
|---|---|---|
| Relative Strength Index (RSI) | 39.79 | 48.78 |
| Support Level | $0.50 | $2.20 |
| Resistance Level | $0.82 | $8.97 |
| Average True Range (ATR) | 0.04 | 0.88 |
| MACD | -0.01 | -0.27 |
| Stochastic Oscillator | 0.18 | 16.91 |
Beyond Meat Inc is a provider of plant-based meat company offering a portfolio of revolutionary plant-based meats. It builds meat directly from plants, an innovation that enables consumers to experience the taste, texture and other sensory attributes of popular animal-based meat products while enjoying the nutritional and environmental benefits of eating plant-based meat product It has products such as burgers, sausage, ground beef, jerky, meatballs and chicken. The company generates revenue from sales of its products to the customers across mainstream grocery, mass merchandiser, club store, convenience store and natural retailer channels and various food-away-from-home channels, including restaurants, foodservice outlets and schools, mainly in the United States.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.